热门资讯> 正文
Pliant Therapeutics将裁员约45%
2025-05-02 22:27
- Pliant Therapeutics (NASDAQ:PLRX) said on Friday that it will cut approximately 45% of its current workforce, across all departments, amid the company's recent restructuring measures.
- The company will complete the process of headcount reduction by the end of the second quarter of 2025.
- "The restructuring aims to minimize costs and preserve cash reserves as the Company awaits topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis," Pliant said in a statement.
- The biopharma company expects topline data from the late-stage trial to be available in the second quarter of 2025.
More on Pliant Therapeutics
- Pliant Therapeutics: An Activist On Deck
- Pliant Therapeutics: Strange Volatility
- Pliant downgraded at Stifel on bexotegrast trial discontinuation
- Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF
- Seeking Alpha’s Quant Rating on Pliant Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
